Nexstone Innovation is a biopharma drug development company established by former partners and senior executives from NeXeption. Members of our team have significant operating experience in small- and large-scale entities, both public and private. We have a successful track record developing small-molecule medicines and large-molecule biologics. Over the past 15 years, we have achieved four FDA-approved products and seven strategic company transactions. Our team is deeply experienced in all aspects of drug development and company operation.
The Nexstone Innovation team partnered with Blackstone Life Sciences to launch Nexstone Immunology, a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-inflammatory/immunology programs in areas of significant unmet medical need. The company's lead program is a monoclonal antibody targeting critical inflammatory pathways. We are currently planning our development program which will evaluate the compound in a broad array of immune-mediated diseases.. Learn more here .
Copyright © 2022 Nexstone Innovation LLC - All Rights Reserved.